Glaukos Corporation develops pharmaceutical and medical device treatments for eye conditions including glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes micro-bypass stents for glaucoma management, an injectable pressure-reduction therapy, a corneal cross-linking device, a topical delivery platform for eyelid application, and a retinal treatment system for conditions like macular degeneration and diabetic eye disease. The company distributes its products to surgery centers, hospitals, and private practices in the United States and internationally.

entry readiness 4 · NOT READY · exit proximity 78

Value area 134.10–188.90 · 0% of 120d volume overhead · clean runway